Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of M
2 Safer High-Yield Stocks That Can Pay Boomers for Life
11:04am, Wednesday, 22'nd Oct 2025
Baby Boomers should be looking to play things a bit more cautiously as stock valuations begin to climb across the board.
My Top 3 Pharma Stocks
11:38am, Monday, 20'th Oct 2025
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and o
Pfizer's Q3 Non-Oncology Performance: Here's What to Expect
11:15am, Monday, 20'th Oct 2025
Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.
– Data demonstrated that vepdegestrant maintained patients' quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including
2 High-Yield Dividend Stocks Too Cheap to Ignore
10:57am, Sunday, 19'th Oct 2025
What's even better than a solid, reliable dividend stock? A solid, reliable, high-yield dividend stock.
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
04:15am, Sunday, 19'th Oct 2025
NEW YORK & NORTHBROOK, Ill.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) result
Pfizer's BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
02:30am, Sunday, 19'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for
Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients
10:37am, Saturday, 18'th Oct 2025
Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, progression or death in patients suffering from a type of bladder cancer, the comp
Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients
10:30am, Saturday, 18'th Oct 2025
Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with an aggressive form of bladder cancer.
First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancer Unprecedented survival result
Pfizer: World-Leading Drug Pipeline Sets Stage For Major Long-Term Potential
08:36am, Saturday, 18'th Oct 2025
Pfizer is rated a buy due to its robust drug pipeline, focus on improving financials, and significant long-term growth potential despite near-term headwinds. PFE delivered strong results in H1, with 1
Interest Rates Tumble: Grab Our 5 All-Time Favorite Safe 6%+ Dividend Stocks
07:49pm, Friday, 17'th Oct 2025
Investors love dividend stocks, especially those with safe high yields, because they provide a substantial income stream and offer significant total return potential.
Pfizer (PFE) Beats Stock Market Upswing: What Investors Need to Know
06:45pm, Friday, 17'th Oct 2025
Pfizer (PFE) concluded the recent trading session at $24.51, signifying a +1.16% move from its prior day's close.
Popular birth control is linked to brain tumors in new study — as over 1,000 women sue Pfizer over health risks
02:57pm, Friday, 17'th Oct 2025
One Louisiana woman, Robin Phillip, said she developed an intracranial meningioma that caused her to lose vision in her left eye and struggle to walk.
